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Spontaneous mutations in the SHANK-associated RH domain interacting protein (Sharpin)
resulted in a severe autoinflammatory type of chronic proliferative dermatitis, inflammation
in other organs, and lymphoid organ defects. To determine whether cell-type restricted loss
of Sharpin causes similar lesions, a conditional null mutant was created. Ubiquitously
expressing cre-recombinase recapitulated the phenotype seen in spontaneous mutant
mice. Limiting expression to keratinocytes (using a Krt14-cre) induced a chronic eosinophilic
dermatitis, but no inflammation in other organs or lymphoid organ defects. The dermatitis
was associated with a markedly increased concentration of serum IgE and IL18. Crosses
with S100a4-cre resulted in milder skin lesions and moderate to severe arthritis. This condi-
tional null mutant will enable more detailed studies on the role of SHARPIN in regulating
NFkB and inflammation, while the Krt14-Sharpin-/- provides a new model to study atopic
dermatitis.
Introduction
Spontaneous mutations in SHANK-associated RH domain interacting protein (Sharpin) result
in a chronic proliferative dermatitis (allele symbol: cpdm) phenotype in two different strains of
laboratory mice (C57BL/KaLawRij-Sharpincpdm/RijSunJ and CBy.OcB3/Dem-Sharpincpdm-
Dem) [1, 2]. In the Sharpincpdm mutant mice, a single base pair deletion was observed resulting
in a shift of the open reading frame predicted to cause an early stop codon beginning at posi-
tion 624 (numbered sequence is based on Ensembl cDNA transcript ENSMUST00000023211).
The Sharpincpdm-Dem mutants there was a C to A transition at position 434 in Exon 1 followed
by a 14-bp deletion where the 14-bp deletion disrupted the reading frame resulting in an early
stop codon. Western blot analysis confirmed loss of SHARPIN protein resulting in both alleles
being null mutations [2].
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In both mutant mouse strains, homozygous mutants develop a severe, chronic, autoinflam-
matory disease, affecting multiple organs but especially the skin, where it is typified by progres-
sive epidermal hyperplasia, marked apoptosis of keratinocytes, and a mixed, primarily
eosinophilic, dermal inflammation. Homozygous mutant mice exhibit multi-organ eosino-
philic inflammation, defective TH1 cytokine production, abnormal T cell development, dimin-
ished immunoglobulin isotype switching, splenomegaly, early regression of Peyer’s patches,
and an absence of B cell follicles, follicular dendritic cells, and germinal centers in secondary
lymph organs [3–5]. This phenotype is consistent in both spontaneous null alleles; however,
CBy.OcB3/Dem-Sharpincpdm-Dem mice have a more rapid onset of symptoms and a shorter life-
span, reflecting strain specific effects [6].
SHARPIN is a highly conserved protein that is widely expressed in cells and tissues of mam-
malian species. It contains three domains, an amino-terminal coiled-coil (CC) domain, an ubi-
quitin-like (UBL) domain, and an Npl4 zinc finger (NZF) domain [7–9]. SHARPIN was
originally described as a structural component of the postsynaptic density of the excitatory
synapse in the rat brain where it interacts with SHANK proteins via its CC domain [10]. More
recently, SHARPIN was identified as a component of the linear ubiquitin chain assembly com-
plex (LUBAC) which is required for activation of the NFkB signaling pathway [11–14].
LUBAC is composed of an E3 ubiquitin ligase, RING finger protein 31 (RNF31, also known as
HOIP), associated with RanBP-type and C3HC4-type zinc finger-containing protein 1
(RBCK1, also known as HOIL1) and SHARPIN. TNF induced cell death is a driver of the cell
death seen in the skin of Sharpincpdm mice as evidenced by the sensitivity of SHARPIN-defi-
cient cells to TNF-induced necroptosis and the lack of dermatitis in TNF-deficient Sharpincpdm
mice [15, 16] TNFR1 results in recruitment of LUBAC to a signaling complex that initiates
NFkB signaling. LUBAC catalyzes the addition of linear ubiquitin chains, connected by Met1
linkages, to RIPK1 and NEMO. The degree of ubiquitination is carefully controlled by deubi-
quitinases, in particular the ubiquitin carboxyl-terminal hydrolase CYLD that hydrolyzes
Lys63 and Met1 linkages, and OTULIN that is specific for linear ubiquitin chains [17–19]. Pre-
liminary observations of compound mutant mice (Sharpincpdm and Cyldtm1Scs) suggest that the
Sharpincpdm phenotype may be due to the failure to inactivate CYLD (https://www.biorxiv.org/
content/10.1101/2020.01.27.919076v1.full). Genetically determined deficiencies in RNF31 and
RBCK1 cause immune deficiency, autoinflammatory disease, and glycogen storage disease in
human patients [20–23], whereas absence of OTULIN has been reported in six patients with
an autoinflammatory syndrome [24, 25].
Fibroblasts, B cells, and dendritic cells isolated from patients or mice deficient in LUBAC
components have decreased NFkB signaling in response to TNF and TLR agonists resulting in
decreased activation and secretion of cytokines. These findings seem inconsistent with the
inflammatory phenotype of LUBAC-deficient patients and mice. Similarly, the association of
autoinflammatory disease with both increased and decreased linear ubiquitination and the
coexistence of immunodeficiency and autoinflammation in RNF31- and RBCK1-deficient
patients seem contradictory. Fibroblasts from patients multi-organ autoinflammation, immu-
nodeficiency, and amylopectinosis due to loss of function mutations in RBCK1 and RNF31
exhibited diminished IL1B- and TNF-induced NFκB activation yet monocytes were hyper-
responsive to IL1B [26]. These observations point to tissue and cell-specific roles of factors
associated with linear ubiquitination. This is also suggested by the reduced response to IL1B in
fibroblasts and increased response in whole blood or monocyte cultures from patients with
RBCK1- and RNF31-deficiency [21]. In Sharpincpdm mice IL1B modulates the cutaneous
inflammation [27]. In addition to the role of SHARPIN as a structural component of the excit-
atory synapse and of LUBAC, SHARPIN suppresses B1-integrin activation [28, 29]. There are
many other molecular pathways affected directly and indirectly [15, 16, 30–34].
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To date, absence of SHARPIN has not been reported in human patients. However, autoso-
mal defects in LUBAC, which SHARPIN is part of, are associated with autoinflammatory and
immunodeficiency diseases in humans [35]. Increased expression of SHARPIN was reported
in different types of cancers in human patients and appears to be associated with increased
malignant behavior [36–41]. This may be in part due to its role in increasing neovasculariza-
tion in cancer models [42].
The mechanism of carbon tetrachloride and acetaminophen-induced hepatic cirrhosis in
mice was shown to be the effects of reduction of SHARPIN in the liver of treated mice [43]
and it may play a role in nonalcoholic steatohepatitis [44].
The complex phenotype affecting multiple organ systems evidenced in Sharpinmutant
mice suggests that Sharpin function may vary according to cell type. Many of the studies that
detail the biochemical studies of SHARPIN function cited above were done in vitro using
immortalized mouse embryonic fibroblast cell cultures. In primary cell cultures SHARPIN
deficiency sensitized mouse and human keratinocytes as well as mouse embryonic fibroblasts
to TNF-induced apoptosis [15]. We hypothesized that the variation in results was because the
mouse Sharpin gene is primarily expressed in keratinocytes not fibroblasts. To investigate this,
a conditional Sharpin null (B6(Cg)-Tyrc-2J Sharpintm1Sun/Sun) was created that developed large
differences in disease severity, anatomic involvement, to normality depending upon which
cre-recombinase was used indicating anatomic site specificity.
Methods and materials
Source and management of mice
All mice were maintained in the humidity, temperature, and light cycle (12:12) controlled
vivarium under specific pathogen-free conditions (http://jaxmice.jax.org/genetichealth/
health_program.html). Mice were housed in double-pen polycarbonate cages (330 cm2 floor
area) at a maximum capacity of four mice per pen. Mice were allowed free access to autoclaved
food (NIH 31, 6% fat; LabDiet 5K52, Purina Mills, St. Louis, MO) and acidified water (pH 2.8–
3.2). All work was done with the approval of The Jackson Laboratory Animal Care and Use
Committee under approval number 07005.
All mice used in these studies were obtained from or created at The Jackson Laboratory
(Bar Harbor, ME). The neo cassette was removed by reciprocal matings between homozygous
B6(Cg)-Tyrc-2J (stock no. 000058), B6(Cg)-Sharpintm1Sun/Sun to create an albino strain. Mice
negative for the neo cassette were bred back to the strain of origin, B6(Cg)-Tyrc-2J/J to remove
the flp allele and mice heterozygous for Sharpin and flp negative were mated to produce a
homozygous colony. B6. Cg-Tg(ACTFLPe)9205Dym/J (stock no. 005703), both homozygous
female and male mice, were mated to homozygous female and male B6(Cg)-Tyrc-2J Shar-
pintm1.1Sun/Sun mice to remove the neo cassette (stock no. 012631). The resulting mice were
crossed with BALB/c-Tg(CMV-cre)1Cgn/J (stock no. 003465) or B6.C-Tg(CMV-cre)1Cgn/J
(stock no. 006054) to remove Sharpin expression in all cells (ubiquitous expression). In order
to only remove Sharpin expression from keratinocytes, B6(Cg)-Tyrc-2J Sharpintm1Sun/Sun with
the neo removed were crossed with STOCK Tg(KRT14-cre)1Amc/J (stock no. 004782). To
eliminate Sharpin expression from adipocytes, hemizygous male B6.FVB-Tg(Adipoq-cre)
1Evdr/J (stock no. 010803) mice were mated to female B6(Cg)-Tyrc-2J Sharpintm1Sun/Sun. To
remove Sharpin from fibroblasts the mice were crossed with BALB/c-Tg(S100a4-cre)1Eng/
YunkJ (stock no. 012641). F1 mice, heterozygous for both Sharpin and cre-recombinase, were
crossed to produce F2s that were genotyped for Sharpin and for cre-recombinase using the
generic cre quantitative QPCR using protocols described on The Jackson Laboratory’s website
(http://jaxmice.jax.org) for the respective strain.
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Creation of Sharpin conditional null mice
To create a conditional knockout line, a Sharpin conditional targeting vector was generated
using standard recombineering techniques [45]. A mini-retrieval vector was prepared using
PCR products of 500 bp for the 5’ and 3’ mini homology segments (Sharpin 5’ret-F 5’-GCGG
CCGCAACTCAGCACTGGCTGACAG-3’ and Sharpin 5’ret-R 5’GGATCC GCTGCAGTGCCT
CATGGGAC-3’ and Sharpin 3’ret-F 5’-GGATCCAGGCGACCCAGCATAGAA-3’, Sharpin
3’ret-R 5’-CTCGAGTGAGCTCAAGGTTCATGCATG-3’) which contained restriction sites
for cloning into pBlight (a plasmid with a MCI_TK cassette downstream of the 3’ retrieval
arm, gift of S. Warming [45]). The linearized mini-retrieval vector was used to retrieve 9.6 kb
of Sharpin and flanking genomic sequence from BAC RP23-204K8 (Children’s Hospital Oak-
land Research Institute, Oakland, CA) by gap repair. The retrieved genomic sequence con-
tained the entire Sharpin gene of 4.07 kb including 9 exons of which 8 are coding, as well as
978 bp ofMaf1 sequence 5’ of the Sharpin gene, and the 2.1 kb gene sequence for Cyc1 present
within the region comprising the 4kb 3’ homology arm. The placement of the frt-PGK-neo-frt
cassette was designed to avoid repetitive sequences in intron 2 of Sharpin using the online
application RepeatMasker (http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker). Exons
3–9 of the Sharpin gene (3kb) were floxed using loxP sites that were inserted by recombineer-
ing. On the 3’ end of exon 9 a floxed neo cassette was engineered that was subsequently
exposed to cre-recombinase to leave a single loxP site on the 5’ end of Sharpin exons 3–9. In
intron 2, a frt-PGK-neo-frt loxP cassette was inserted by recombineering, to effectively flank
functionally essential parts of the gene with loxP sites for removal in a temporal and spatial
manner by breeding to a cre-expressing strain. The PGK-neo cassette was flanked by frt
sequences to facilitate its removal independent of the loxP. The frt-PGK-neo-frt-loxP cassette
was preceded by a 2.3 kB arm of the Sharpin gene sequence. 3’ of the floxed Sharpin exons is
4kb of sequence comprising the 3’ retrieval arm (Fig 1A).
The correct sequence was confirmed by Sanger sequencing. The plasmid was purified using
the Midi-prep kit (Qiagen, Valencia, CA).
Plasmid DNA (60 ug) was linearized with Sspl precipitated with ethanol and submitted to
the Cell Biology Core at The Jackson Laboratory for B6-Tyr embryonic stem (ES) cell electro-
poration. Stably transfected cells were selected by G418 resistance. A total of 360 B6-Tyr ES cell
clones were screened for homologous insertion of the transgene by Southern blot after diges-
tion with DraIII, using as a probe a PCR product (primers Forward 5'- AGCTTACCTGCT
GGGACTGAGG-30 and Reverse 5'- GGAGCTAGGTAGCCATGCTGG -3') whose sequence
lay outside of the 5’ homology arm.
Primers used for the detection of Sharpin post flp and post cre were GGGATGTATCTGTCA
GGGAAC-mutant, GCCCTTGGAGGCTATTTGTT -common, and GCCCAGCTTTTCCATCAC
TA -wildtype reverse.
Phenotyping mutant mice
For each comparison conducted in this study, age matched female and male mutant and con-
trol mice were collected, euthanized by CO2 asphyxiation using approved methods, and com-
plete necropsies performed using previously described methods [46]. Briefly, hematoxylin and
eosin (H&E) stained slides were examined by experienced board certified veterinary anatomic
pathologists (JPS, HH) and all lesions subjectively scored (normal, 0; mild, 1; moderate, 2;
severe, 3; extreme, 4) and data (with diagnosis and anatomic site) entered into the Mouse Dis-
ease Information Database (MoDIS) [47]. These data were used to generate spreadsheets for
semi-quantitative analysis. Morphometric analyses of tissue sections were conducted to deter-
mine epidermal thickness (dorsal interscapular skin) along the linear length of sample. In each
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case, five measurements were made along an H&E stained section of dorsal skin from each
mouse. The thickness of the Malpighian layer (basement membrane to the base of the stratum
corneum) was measured in vertical sections (perpendicular to the basement membrane) in
which the entire length of the hair follicle was visible in the field to assure consistent
Fig 1. Identification of correctly targeted ES cell clones. Homologous recombination between the Sharpin cko-targeting vector and the Sharpin
genomic locus, flanked by Cyc1 andMaf1. The correctly targeted locus is 12kb, when mated to Flpe, the removal of neo will leave a 10.3 kb targeted allele
and mating to various cre-recombinase strains will leave 7kb for the Sharpin-/- allele. LoxP sites are depicted by white triangles and frt sites by black
triangles (A). Southern blot analysis of the ES cell clones. (B6+/+) Wild-type ES clones; (B6 Sharpin) conditional knockout ES clones. Correctly targeted
ES cells (cko allele) have a 5.0-kb DraIII band, the wild type allele shows 8.5 kb band, following hybridization with the 5’ probe (B). Genotyping assay for
Sharpin alleles. Primers were designed to discriminate between the Sharpin alleles, WT+/+, het +/-, and null -/-. Arrows point to the expected size band,
wild-type or Sharpin-/-. Lane 1 shows molecular weight marker (C). Neo copy Sharpin. A copy number QPCR assay was performed on the various
Sharpin alleles. Lane 1 and 2- BL6 Tyrc-2J and BALB WT do not contain any neo copies, lane 3–27454 Sharpin het (+/-) post cre, pre Flpe shows a single
neo copy, lanes 4 and 5 are homozygous null pre Flpe, and lane 6 is BL6-1 after Flpemating (D). Sharpin loss of allele (LOA). QPCR LOA assay was
performed to detect the presence of absence of the Sharpin exon 4. The first 2 het samples show the loss of a Sharpin allele as compared with the WT
sample (E).
https://doi.org/10.1371/journal.pone.0235295.g001
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orientation. Stratum corneum was measured immediately above the Malpighian layer. The
thicknesses of both layers were added to yield the total epidermal thickness of the sample. Mea-
surements were done manually at 400x magnification using a DP27 digital camera on a
BX50F4 photomicroscope (Olympus, Tokyo, Japan) and DP controller 3.2 software (Olympus,
Center Valley, PA) by one pathologist (JPS).
Hematology
Whole blood (200 μl) was collected in soda lime glass micro-hematocrit capillary tubes (stock
no. 51608, Globe Scientific, Paramus, NJ). The uncoagulated blood was run without separation
on a Siemens Advia 2120 Hematology Analyzer (Siemens Healthcare Diagnostics Inc., Tarry-
town, NY).
Immunohistochemistry
To determine where SHARPIN protein was expressed, immunohistochemistry was done
using a Ventana XT autostainer (Tuscon, AZ) with an antibody directed against SHARPIN
(Sharpin (Y-14) stock no. sc~98129, Santa Cruz, Dallas, TX). Immunohistochemistry was
tested using 5 different fixatives. Only 4% paraformaldehyde fixed sections worked with this
antibody. For immunohistochemistry, 1 male 121 day old C57BLKaLawRij-Sharpincpdm/Rij-
SunJ (null mutant), 1 male 133 day old C57BLKaLawRij/RijSunJ (wildtype control), one 57
day old CByJ.OcB3-Sharpincpdm-Dem/Sz (null mutant), and 1 CBy.OcB3/Sz (wildtype control)
had skin collected and fixed in 4% paraformaldehyde. Slides were run using a Ventana Discov-
ery XT autostainer (Ventana, Tuscon, AZ) with diaminobenzidine (Sigma, St. Louis, MO)
used as chromogen.
Quantitative real-time RT-PCR (qRT-PCR) to genotype for Sharpin
The expression of mRNA in the skin of 4-week old mice was determined by qRT-PCR [48].
Skin from 4 weeks of age/sex matched mice was collected and stored in RNALater (Qiagen,
Valencia, CA) at -80˚C until samples from all replicates were collected. RNA was then
extracted using a PureLink RNA Mini Kit (Invitrogen, Grand Island, NY). For each qRT-PCR,
a 15ul reaction was run with 7.5 μl Taqman One-Step RT-PCR Master Mix 2X (Life Technolo-
gies, Grand Island, NY), 0.4ul, 40X Multiscribe and Rnase Inhibitor Mix, 0.75 μl of 20X Assays
on Demand Taqman primer and probe set and 100ng RNA. The qRT-PCR was performed in a
Mastercycler1 realplex4 (Eppendorf, Hauppauge, NY) programmed at 40 cycles of 42 C for
50 minutes, 90 C for 10 minutes, 95 C for 15 seconds, 60 C for 1 minute, and 72 C for 1 minute.
The Ct values for each chemokine were normalized by subtracting the Ct values for the house-
keeping gene Actb (Delta Ct). The relative fold-change in mRNA expression between wild-
type mice and mutant mice was calculated by the 2-(delta-delta Ct) method [49].
Localization of gene expression for cre-recombinase transgenic mice
While a review of the literature can suggest where genes are naturally expressed, it is always
important to verify this when various promoters are used with cre-recombinases. To do this,
slides were obtained from the Comprehensive cre Characterization Resource at The Jackson
Laboratory where whole slide scanned images of embryos (E15.5) or tissues (at P7 and P56)
can be viewed online (http://www.informatics.jax.org/home/recombinase) [50]. The slides
were created using frozen sections of tissues (or embryos) from crosses between each of the
cre-recombinase transgenic mice listed above and B6.129S4-Gt (Rosa) 26Sortm1Sor/J (Stock No.
3474). Fresh frozen sections were labeled as previously described [51].
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Serum immunoglobulins and serum IL-18
Concentrations of serum IgM, IgG, IgA, and IgE were determined by ELISA using isotype-
specific reagents obtained from Southern Biotech (Birmingham, AL) as previously described
[3]). The concentration of IL18 in serum of mice was determined using a commercially avail-
able ELISA (MBL International, Woburn, MA).
Cytokines
RNA isolation and analysis from skin samples was done as previously described [52]. Skin sam-
ples collected from the left side of mice were homogenized in TRI-reagent (Sigma-Aldrich).
Total RNA was isolated by standard TRI-reagent methods according to the manufacturer’s pro-
tocols and quantitated at 260 nm. RNA was analyzed by quantitative real time RT-PCR (qPCR)
and custom eTags™ multiplex assays (ACLARA Biosciences, Mountain View, CA).
For qPCR, RNA was reverse transcribed for 1 hour at 42˚C in 30μL volumes containing
0.5μg RNA, 2.8U Recombinant RNasin Ribonuclease Inhibitor, 400U M-MLV Reverse Tran-
scriptase, 6.0μL M-MLV Reverse Transcriptase 5X buffer, 0.25μg Oligo(dT) 15 Primer, and
0.5mM of each nucleotide (Promega, Madison, WI) in a Peltier Thermal Cycler 200 (MJ
Research/Bio-Rad Laboratories, Waltham, MA). The cDNA was analyzed with Assays on
Demand Taqman1 primer and probe sets following the manufacturer’s instructions using the
7300 Real Time PCR System and Sequence Detection Software v1.2.1 (Applied Biosystems,
Foster City, CA). The Ct values for each chemokine were normalized by subtracting the Ct val-
ues for the housekeeping gene actin beta (Actb, ID Mm00607939_s1). The difference in
mRNA expression between mice was calculated with the difference in normalized Ct values
(fold change = 2−ΔΔCt) [49].
Statistical analysis
Graphs and descriptive statistics were generated in GraphPad Prism Version 8.3.1. The statisti-
cal significance of differences between means of experimental groups for epidermal thickness,
expression of mRNA and protein concentrations was determined by two-tailed Student’s t-test
using Microsoft1 Excel and GraphPad Prism. Differences were considered significant at
p< 0.05.
Results
Creation of the conditional Sharpin allelic mutation
The wild-type Sharpin allele consists of 9 exons, which encode 387 amino acids, producing a
40kd protein (Fig 1). An alternative start site is hypothesized to exist at exon 6 that encodes a
60 kd splice variant (www.ensembl.org). Given the high number of repetitive sequences in
intron 2, a targeting vector was constructed in which exons 3–9 were flanked by Frt-neo-Frt-
loxP and loxp sites.
Mice positively expressing the new allele that also contained the Frt-neo-Frt-cassette had
the latter cassette removed by crossing the mice with by reciprocal matings between homozy-
gous B6(Cg)-Tyrc-2J and B6(Cg)-Sharpintm1Sun/Sun, to create an albino stock, and B6.Cg-Tg
(ACTFLPe)9205Dym/J mice (Fig 1). Mice negative for the neo cassette were bred back to the
strain of origin, B6(Cg)-Tyrc-2J/J to remove the flp allele and mice heterozygous for Sharpin
and flp negative were mated to produce a homozygous colony. Once viable conditional Shar-
pin null (B6(Cg)-Tyrc-2J Sharpintm1.1Sun/Sun, hereafter referred to as Sharpin-/-) mice were con-
firmed, crosses were established with transgenic mice carrying cell specific promoters driving
cre-recombinase in order to ubiquitously or selectively inactivate Sharpin.
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Expression of SHARPIN protein in various organs
To determine the distribution of SHARPIN protein expression, immunohistochemistry was
done on tissues from wild type controls and Sharpincpdm mutant mice. Tissues from the Shar-
pincpdm null mice were negative (except for endogenous peroxidase activity in a few cells such
as mast cells) which served as a negative control. SHARPIN was not expressed in the liver,
Peyer’s patches, or intestine. However, SHARPIN was detected in epithelial cells of the skin
and hair follicles, foot pad, eccrine gland, tongue, lingual gland, esophagus, hard palate, nasal
epithelium, tooth (ameloblasts), nail unit (hyponychium and proximal nail fold), forestomach,
cornea and lens of the eye, and Purkinje cells of the cerebellum (Fig 2).
Expression of cre-recombinases in the skin
To verify that the transgenic mice carrying cre-recombinases expressed the cre where it was
expected, they were crossed with transgenic mice carrying a LacZ reporter. The CMV ubiqui-
tously expressing cre-recombinase exhibited widespread expression on the BALB/c and
C57BL/6 background (data not shown). Krt14-cre transgene was expressed in the epidermis
Fig 2. Immunohistochemical localization of SHARPIN protein. SHARPIN protein was normally expressed in the epidermis and hair follicles (A) of wild type, control
mice (N = 2) but not in the spontaneous chronic proliferative dermatitis (Sharpincpdm/cpdm) null mutant mice (N = 2, B), which served as a negative control. In normal wild
type mice SHARPIN was not expressed in the liver (C), Peyer’s patches, or intestine (E). However, SHARPIN was expressed in epithelial cells of the foot pad (D) and
eccrine gland (D, I), tongue (F), lingual gland (G), esophagus (H), hard palate (M) and nasal epithelium (M and insert), tooth (ameloblasts) (K), nail unit (hyponychium
and proximal nail fold, L, P, Q), forestomach (N), cornea and lens of the eye (O), and Purkinje cells of the cerebellum (J).
https://doi.org/10.1371/journal.pone.0235295.g002
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and hair follicles (and other epidermal structures) similar to immunohistochemical localiza-
tion of KRT14 (S1A Fig) [53]. S100 calcium binding protein A4 (S100A4) is still published as
fibroblast-specific protein [54], but the S100-cre transgene was detected in the epidermis and
infundibulum of hair follicles (S1B Fig). S100a4-cre transgenic mice exhibited less expression
in basal keratinocytes and the base of hair follicles relative to the Krt14-cremice which proba-
bly accounts for the reduced severity when crossed with the inducible Sharpin null mice. The
Adipoq-cre transgene was expressed in adipose tissue (S1C Fig). Additional images are avail-
able online (http://www.informatics.jax.org/home/recombinase) [50].
Overall comparisons of phenotypes
Control mice and all crosses survived until at least 10 weeks of age with exception of the B6-
CMV-cre Sharpin-/- mice (hereafter all compound mutants will have cre left out), most of
which died by 6 weeks of age. Therefore, most of the comparative studies were done at 6 weeks
of age. BALB-CMV Sharpin-/-, B6-CMV Sharpin-/-, and Krt14 Sharpin-/- mutant mice devel-
oped extensive dermatitis similar to the two spontaneous allelic null mutations, Sharpincpdm/
cpdm and Sharpincpdm-Dem/cpdm-Dem with no sexual dimorphism [1, 2]. The mice had severe pru-
ritus and scratched frequently which led to skin erosions and ulcers necessitating euthanasia at
8–10 weeks of age for the BALB-CMV Sharpin-/- and Krt14 Sharpin-/- mice.
Body weights were measured on at least 5 mice of each genotype, females and males. Males
were consistently higher in weight than females. Control mice and mutant mice with no or
mild skin lesions gained weight during the 4–10 week of age observation period (S2 Fig).
Degree of failure to gain weight reflected the severity of systemic disease in each cross due to
loss of Sharpin. The ubiquitously expressing cre-recombinases resulted in the most severe dis-
ease and failure to survive or gain weight. Those with primarily skin lesions (Krt14 cross) were
moderately affected. Those with no (Adipoq) or relatively minor lesions, primarly referring to
the skin disease (S100a4) were within or at the bottom of the normal range for gain of body
weight. The B6-CMV Sharpin-/- mice gained little weight until they died by 6 weeks of age. The
BALB-CMV Sharpin-/- mice gained some weight but lagged below the other crosses. The Krt14
Sharpin-/- mice had moderate weight gain but less than the control mice whereas S100a4 Shar-
pin-/- and Adipoq Sharpin-/- mice were within the normal range for body weight.
Mice carrying the spontaneous Sharpincpdm/cpdm mutation had marked changes in the
peripheral blood white blood cell count and differentials [6]. Changes in the blood confirmed
the chronic proliferative dermatitis phenotype in the ubiquitously expressing CMV Sharpin-/-
mutant mice on both backgrounds but with a high degree of variability between individuals.
However, there was a significant increase of neutrophils in both the Krt14 and S100a4 Shar-
pin-/- mice, but only eosinophils for the Krt14 Sharpinmutant mice (S3 Fig). As with the spon-
taneous Sharpin null mice [6], there was no sexual dichotomy. There was no change in the
peripheral blood for the Adipoq Sharpin-/- mutant mice.
Epidermal hyperplasia is a hallmark of the chronic proliferative dermatitis phenotype [1, 6]
and a useful marker for quantitative assessment of the dermatitis. The thickness of both the
Malpighian layer (stratum basale and stratum spinosum) and the stratum corneum in both the
B6-CMV Sharpin-/- and BALB-CMV Sharpin-/- mutant mice was significantly greater than the
controls, similar to that found the two spontaneous allelic null mutations (Sharpincpdm/cpdm
and Sharpincpdm-Dem/cpdm-Dem) (Fig 3) [6]. Krt14 Sharpin-/- mice had a similar increase of epi-
dermal thickness as mice with ubiquitously deleted Sharpin. The S100a4 Sharpin-/- mice had a
thicker epidermis than controls but it was significantly less so than the CMV Sharpin-/- and
Krt14 Sharpin-/- crosses. There was no difference in epidermal thickness between the Adipoq
Sharpin-/- and control mice (Fig 3).
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Cre-specific phenotypes
Lesions varied by their presence or absence in different organs as well as the severity in specific
organs based on the cre-recombinase used. Lesions were compared with those in the spontane-
ous null allele Sharpincpdm/cpdm (Table 1). Major lesions are described by each cross and the
accompanying figures compare lesions from the same sites for all the crosses.
Fig 3. Changes in epidermal thickness. There was a significant difference in thickness of the stratum basale and stratum spinosum (SB-SSp) and the stratum corneum
(SC) between the control mice (WT) and B6-CMV, C-CMV, Krt14, and S100a4 Sharpin-/- mutant mice (�� p< 0.01). Epidermal thickness was similar in the Krt14
Sharpin-/- to those ubiquitously expressing CMV-cre, but less in S100a4 Sharpin-/- mice. The Adipoq Sharpin-/- mutant mice were unaffected, identical to the controls.
Bars represent the mean + SEM of 4–10 mice per group. ND–not done.
https://doi.org/10.1371/journal.pone.0235295.g003
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F1 mice heterozygous for both Sharpin and cre-recombinase were crossed to produce F2
mice that were genotyped for Sharpin and for cre using quantitative QPCR. All genotypes were
evaluated but only those homozygous for Sharpintm1.1Sun and homozygous or heterozygous for
the cre-recombinase developed lesions. Results were similar in mice carrying one or both cop-
ies of the cre-recombinase.
B6(Cg)-Tyrc-2J Sharpintm1Sun/Sun mice recapitulate the cpdm phenotype when crossed
to mice ubiquitously expressing cre-recombinase. Conditional Sharpin null mice were
crossed with a CMV ubiquitously expressing cre-recombinase on two different genetic back-
grounds. The BALB/c transgenic line was initially available, which resulted in a hybrid stock,
potentially complicating interpretation of the phenotype. When the B6 transgenic line became
available this construct was also used.
Lesions were largely similar to what has been earlier described in Sharpincpdm/cpdm and
Sharpincpdm-Dem/cpdm-Dem mice with the spontaneous null mutation [1, 6, 55]. The mice had
prominent skin lesions (Fig 4). The epidermis contained scattered apoptotic keratinocytes
(arrow, Fig 4E) and was significantly increased in thickness as a result of acanthosis and ortho-
and parakeratotic hyperkeratosis (Fig 3). There was inflammation of the dermis comprised of
accumulations of granulocytes and macrophages. Eosinophils were also present in the epider-
mis and occasionally formed intracorneal and subcorneal pustules. There were increased num-
bers of cross-sections of small blood vessels in the dermis as found in the spontaneous mutants
[56]. The dermis of older mice had an increase of collagen deposition (fibrosis).
There was moderate to severe hyperplasia of the epithelium of the esophagus with scattered
apoptotic epithelial cells (data not shown). The cornified layer of the epithelium was thickened
and there was accumulation of eosinophils in the subepithelial propria mucosae and the basal
layer of the epithelium. Changes were similar to those described in Sharpincpdm/cpdm mice [57].
Changes in the forestomach varied from the presence of a few apoptotic epithelial cells to
marked and diffuse thickening of the epithelium (S4 Fig). A few inflammatory cells, mostly
eosinophils, were present in the subepithelial connective tissue. Mild hyperplasia and a few
apoptotic epithelial cells were observed on the epithelium of the oral cavity. These changes
resemble those found in the spontaneous mutant mice [57].
There was mild to extensive inflammation in the portal areas and surrounding the central
veins of the liver (S5 Fig), and around the bronchioles and blood vasculature of the lungs (S6
Fig). The inflammation in the liver consisted mostly of a mixed population of granulocytes
and macrophages with mild fibrosis. In the lungs, the majority of cells were lymphocytic with
fewer granulocytes and macrophages. Inflammatory changes were observed in the joints of
some mice (S7 and S8 Figs). The most severely affected joint was the humeroscapular (shoul-
der joint) with accumulation of granulocytes in the synovial membrane and surrounding tis-
sues and fibrosis. Milder changes were seen in the knee joints. Similar inflammatory changes
were observed in the middle ear (S9 Fig).
Table 1. Histologic lesions in wild type and mutant 6 week old mice. Note variation in lesion distribution and severity based on where SHARPIN was deleted.
Strain Skin Forestomach Liver Lung Shoulder Knee Middle Ear Peyer’s Patch Spleen Lymph Node
Sharpin +/- Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
Sharpincpdm/cpdm Severe Severe Severe Severe Severe Severe Severe Missing Severe Severe
BALB-CMV-cre Sharpin-/- Severe Severe Severe Mild Variable Minimal Severe Missing Severe Severe
B6-CMV-cre Sharpin-/- Severe Severe Severe Severe Normal Mild Severe Missing Severe Severe
Krt14-cre Sharpin-/- Severe Normal Normal Normal Normal Normal Normal Normal Normal Normal
S100a4-cre Sharpin-/- Mild Normal Normal Severe Severe Mild Normal Normal Normal Mild
Adipoq-cre Sharpin-/- Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
https://doi.org/10.1371/journal.pone.0235295.t001
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Fig 4. Dorsal skin histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or
only one copy of the conditional Sharpin null gene were normal (A). Normal epidermis was thin with few, if any
inflammatory cells in the dermis. However, mice carrying one or two copies of the ubiquitously expressing CMV-cre
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Similar to Sharpincpdm/cpdm mice, in both of the CMV-cre Sharpin-/- strains there was a
nearly complete loss of lymphoid tissues in the small and large intestine (S10 Fig). In younger
mice, small aggregates of lymphocytes often mixed with granulocytes, mostly eosinophils (con-
firmed using eosinophilic major basic protein by immunohistochemistry, data not shown),
could occasionally be found in the submucosa and lamina propria of the small and large intes-
tine. These represent remnants of the Peyer’s patches and large intestinal follicles following a
process of involution as previously described [5].
Well-defined lymphoid follicles were absent from the white pulp of the spleen and from
lymphoid follicles. There was a mild to moderate increase of myelopoiesis in the red pulp (S11
Fig). There was marked lymphoid depletion with effacement of the lymph node by eosinophils
in the spontaneous and ubiquitously deleted Sharpin null mice (S12 Fig). The thymus of Shar-
pincpdm/cpdm mice was often smaller in size, but maintained a well populated cortex which was
clearly separated from the medulla. By contrast, mild to severe involution of the thymus was
present in CMV-cremice. In the mildly affected mice, the overall thymus was markedly
reduced in size, but there was a clearly defined cortex that was densely populated with thymo-
cytes. In more advanced lesions, there was a marked increase of apoptosis of thymocytes in
both the cortex and medulla. In the most advanced lesions, a single remnant of the thymus
could be identified consisting of a small sheet of epithelial cells with few lymphocytes. Cysts
lined by ciliated epithelial cells were present in the thymic remnant of one mouse.
Krt14-cre-recombinase mice. No lesions were observed in the control mice. The epider-
mis of Krt14 Sharpin-/- mice contained numerous apoptotic keratinocytes and had marked
acanthosis and ortho- and parakeratotic hyperkeratosis resulting in a significant increase of
epidermal thickness (Figs 3 and 4E). The increased epidermal thickness was similar to that
seen in the spontaneous and ubiquitously deleted Sharpinmutant mice. There was abundant
mixed cellular inflammation in the dermis. Granulocytes, both eosinophils and neutrophils,
were common in the dermis and epidermis and frequently formed intracorneal or subcorneal
microabscesses. There were occasional apoptotic epithelial cells in the oral mucosa with mild
acanthosis and focal areas of parakeratotic hyperkeratosis. A few granulocytes were present in
the subepithelial propria mucosae and in the epithelium. No changes were observed in the
mucosa of the esophagus or forestomach (S4E Fig) in contrast to Sharpincpdm/cpdm mice with
generalized deletion of the SHARPIN protein. Lymphoid tissues appeared normal including
the presence of Peyer’s patches in the small intestine (S10E Fig) and well-defined lymphoid fol-
licles in lymph nodes (S12E Fig) and spleen (S11E Fig). There was a mild increase of extracellu-
lar hematopoiesis, primarily myelopoiesis, in the red pulp of the spleen of a few mice (S11E
Fig). No evidence of inflammation was present in the liver (S5E Fig), lungs (S6E Fig), joints
(S7E and S8E Figs) or middle ears (S9E Fig) of Krt14 Sharpin-/- mice at 4, 6, and 8 weeks of
age. However, one 10-week-old female mouse had severe inflammation characterized by accu-
mulation of granulocytes and macrophages with fibrosis around central veins and in portal
areas. There were no lesions in the lungs or joints in this mouse.
S100a4-cre-recombinase mice. No lesions were observed in the control mice. The epider-
mis of S100a4 Sharpin-/- mice contained apoptotic keratinocytes and had various degrees of
acanthosis and orthokeratotic hyperkeratosis resulting in mild to moderate increase of epidermal
and homozygous for the conditional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous
Sharpincpdm/cpdm mice (B). The epidermis was moderately to severely acanthotic with orthokeratotic hyperkeratosis.
Apoptosis (arrows) of keratinocytes was common. Dermis had various degrees of inflammation consisting of a mixture
of eosinophils, neutrophils, and macrophages. Lesions were the same for the Krt14mice (E) but much less severe,
although present, in the S100a4mice (F). Adipoq Sharpin-/-were normal. Low magnification 100X, high magnification
400X (G).
https://doi.org/10.1371/journal.pone.0235295.g004
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thickness (Figs 3 and 4F) which were less severe than seen in the ubiquitously deleted Sharpin or
Krt14 Sharpin-/- mice. Mild to moderate mixed cellular inflammation was present in the dermis
with occasional presence of inflammatory cells in the epidermis. By contrast to Sharpincpdm/cpdm
or CMV Sharpin-/- mice with generalized deletion of the SHARPIN protein, lymphoid tissues
appeared normal including the presence of Peyer’s patches in the small intestine (S10F Fig) and
well defined lymphoid follicles in lymph nodes (S12F Fig) and spleen (S11F Fig). There was a
mild to moderate increase of extracellular hematopoiesis and primarily myelopoiesis in the red
pulp of the spleen. The shoulder (humeroscapular) joints of 15 of the 16 mice in which this joint
could be evaluated had severe arthritis characterized by accumulation of fibrin in the joint space
and infiltration of the synovia and surrounding tissues by granulocytes and macrophages (S7F
Fig). Fibrotic changes were occasionally observed. There was no light microscopic evidence of
damage to the articular cartilage. Mild to moderate arthritis and tendinitis was present in the knee
joints of 10 mice. There was also inflammation of the temporomandibular joints in five of 13 mice
in which these tissues could be examined (data not shown). The inflammation varied from mild
accumulation of granulocytes to the presence of fibrin and numerous granulocytes. No evidence
of inflammation was present in the elbow, phalangeal, and intervertebral joints. There was inflam-
mation characterized by accumulation of granulocytes admixed with macrophages in the connec-
tive tissue at the base of the heart of four mice, extending into the base of the aorta in two mice.
There was mild mixed cellular perivascular and peribronchiolar inflammation in the lungs and
inflammation in periportal triads of the liver in one 10-week-old S100a4 Sharpin-/- mouse. The
lungs (S6F Fig) and liver (S5F Fig) of the other S100a4 Sharpin-/- mice had no inflammation.
Adipoq-cre recombinase mice. There were no differences noted between the control mice
and Adipoq Sharpin-/- mice (Fig 3G, S6–S12G Figs).
Serum immunoglobulins and serum IL18
Mice with the spontaneous Sharpincpdm/cpdm mutation have a defect in isotype switching result-
ing in a marked decrease of total serum IgG and IgA, and nearly undetectable IgE (S13 Fig)
[3]. S100a4 Sharpin-/- mice had similar concentrations of IgG, IgA, and IgE as control mice,
and a slightly reduced concentration of IgM (Fig 5). Krt14 Sharpin-/- mice had normal
Fig 5. Serum immunoglobulins. Concentration of immunoglobulin in the serum of Krt14 Sharpin-/- and WT mice (top panels) and S100a4 Sharpin-/- and WT mice
(bottom panels). Bars indicate the mean ± SEM of 3–6 mice per group. � p< 0.05; �� p< 0.01.
https://doi.org/10.1371/journal.pone.0235295.g005
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immunoglobulin concentrations at 4 weeks of age, but significantly increased concentrations
of serum IgG and IgE at 10 weeks of age (Fig 5). These data indicate that these mice with selec-
tive deletion of Sharpin in non-immune cells did not have a defect in isotype switching and,
secondly, demonstrated that the dermatitis in the Krt14 Sharpin-/- mice was associated with a
marked increase of serum IgE.
IL18 induces an increase of IgE in mice [58], and increased concentration of serum IL18
has been reported in human patients with atopic dermatitis [59, 60]. We therefore determined
the concentration of IL18 in the serum of control and mutant mice. There was a significant
increase of IL18 in the serum of Sharpincpdm/cpdm mice compared with control mice (Fig 6). A
similar increase was observed in the serum of Krt14 Sharpin-/- and S100a4 Sharpin-/- mice. The
concentration increased with the age of the mice and the progression of the dermatitis, and
was much higher in the Krt14 Sharpin-/- mice than the other mutant strains.
Cutaneous expression of cytokines and proteases
The spontaneous Sharpincpdm/cpdm null mice developed a persistent dermatitis associated with
increased expression of TH2 cytokines, chitinase-like 3 protein (CHIL3), a sensitive marker of
alternatively activated macrophages, and eosinophil-specific chemokines [4, 48]. The type 2
inflammation may result from lack of SHARPIN in stromal cells, immune cells, or both. To
determine the effect of loss of Sharpin in non-immune cell types on expression of type 1 and
type 2 cytokines, changes in various cytokine mRNA levels were evaluated in CMV, Krt14, and
S100a4 Sharpin-/- mice, and appropriate controls.
The dermatitis in the skin of all mutant mice was associated with a highly significant
(p< 0.0005) increased expression of Chil3 consistent with type 2 inflammation (S14 Fig). This
was supported by the increase of Il4, Il5, and Il13mRNA expression and decreased expression
of Ifng except in the BALB-CMV Sharpin-/- mice (Fig 7). The change in cytokine expression
was greatest in the B6-CMV Sharpin-/- mice and least in the S100a4 Sharpin-/- mice reflecting
the severity of the inflammation observed by light microscopy. These data indicate that the
selective deletion of SHARPIN in stromal cells did not change the type of inflammation.
We previously reported increased expression of the epithelial cytokines thymic stromal
lymphopoietin (TSLP) and IL33 in the skin of Sharpincpdm/cpdm mice [6]. There was significant
increase of Tslp and Il33mRNA in the skin of CMV Sharpin-/- mice, but only an increase of
TslpmRNA and not Il33mRNA in the skin of Krt14 Sharpin-/- mice (Fig 7).
CCL11 (eotaxin) and CCL24 (eotaxin-2) are two eosinophil-specific chemokines that
attract eosinophils into tissues and can induce their activation. We observed significantly
Fig 6. Serum IL18. Concentration of IL18 in the serum of (A) WT and Sharpincpdm mice (5–7 weeks of age, 6 mice/group), (B) Krt14 Sharpin-/- and control mice (4–6
mice/group) and (C) S100a4 Sharpin-/- and control mice (3–5 mice/group). Bars indicate the mean ± SEM. �� p< 0.01; ��� p< 0.001.
https://doi.org/10.1371/journal.pone.0235295.g006
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increased expression of Ccl11 and Ccl24mRNA in the skin of B6-CMV Sharpin-/- mice, but
only increased expression of Ccl24mRNA in the skin of B6-CMV and Krt14 Sharpin-/- mice.
There was no significant increase in the expression of these chemokines in the skin of S100a4
Sharpin-/- mice (Fig 7).
Fig 7. Expression of mRNA of cytokines and inflammation-related proteins in the skin of control and C-CMV Sharpin-/-, B6-CMV
Sharpin-/-, Krt14 Sharpin-/-, and S100a4 Sharpin-/- mice. The fold change of mRNA expression compared with control skin was calculated
using the 2-ΔΔCt method. Bars represent the mean + SEM of 6 mice/group. � p< 0.05; �� p< 0.01; ��� p< 0.001.
https://doi.org/10.1371/journal.pone.0235295.g007
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There was a marked accumulation of mast cells in the skin of Sharpincpdm/cpdm mice [1]. We
examined the expression of mast cell protease genes.Mcpt4 and 5 are specifically expressed by
connective tissue mast cells [61], andMcpt8 by basophils [62]. Surprisingly, there was a signifi-
cant, but modest increase ofMcpt4 andMcpt5mRNA in the skin of B6-CMV Sharpin-/- mice,
but not in the skin of the other mutant mice. By contrast, the expression ofMcpt8mRNA was
increased significantly in all mutant mice. The mast cell protease 9, encoded byMcpt9, was ini-
tially reported to be selective expressed in uterine mast cells in mice [63], but is also expressed
in mast cell lines derived from spleens [64]. The expression ofMcpt9 was increased in all
mutant mice except for the S100a4 Sharpin-/- mice (Fig 7).
Discussion
Correlating the specific cell types in which a gene is highly expressed and its biological func-
tion is not always straightforward. For example, the ATP-binding cassette, sub-family C
(CFTR/MRP), member 6 (Abcc6) gene is normally highly expressed in the liver and to a lesser
extent in the kidney, yet lesions, ectopic mineralization in this case, occur at other anatomical
sites [65]. In this case, the ABCC6 protein acts as a transmembrane ATP efflux transporter. In
other cases, genes can be highly expressed in locations where lesions occur when they are
mutated, such as stearoyl-Coenzyme A desaturase 1 (Scd1), which regulates lipid metabolism
and results in severe abnormalities in sebaceous glands when missing [66]. In the case of the
Sharpin gene, immortalized mouse embryonic fibroblasts have been used extensively to define
its biochemical functions yet the data generated has not always matched experimental results
using live mice carrying spontaneous null mutations in the gene as indicated in the introduc-
tion. Primary cultures of human keratinocytes as well as mouse keratinocytes and embryonic
fibroblasts have been used to study the effect of SHARPIN deficiency on TNF-induced apopto-
sis [12–16]. SHARPIN-deficiency leads to increased sensitivity of these cells as well as myeloid
cells to TNF-induced cell death [16]. Systemic deletion of TNFR1 prevented both the dermati-
tis and inflammation in the liver and lungs [14, 15]. However, specific deletion of TNFR1 in
keratinocytes prevented keratinocyte cell death and dermatitis, but did not ameliorate systemic
inflammation [15]. Both keratinocyte and systemic cell death and inflammation are dependent
on enzymatically active RIPK1 [67]. By contrast, RIPK3 and MLKL-deficiency had no effect
on the dermatitis, but greatly reduced systemic inflammation [16]. This indicates cell and tis-
sue type-specific effects and mechanisms of TNF-induced cell death caused by deficiency of
SHARPIN. To begin to address the role of SHARPIN in specific cell types, a conditional Shar-
pin null mouse was created. Mutant mice were crossed with transgenic strains carrying pro-
motors that drove cre-recombinase expression ubiquitously throughout the body, which
would recapitulate the spontaneous Sharpin null allele phenotypes, or ones that expressed cre
in keratinocytes (Krt14), fibroblasts (S100a4), or adipocytes (Adipoq).
Inbred, congenic, hybrid, or mixed genetic backgrounds often have major effects on single
gene mutations that have a major effect on the health of the mouse which reflects effects of var-
ious modifier genes in one strain versus another [68]. Lack of large-scale standardization of
strain background used to make many of the cre-recombinases can be a problem in some stud-
ies as was in this one. A differential effect in disease severity was observed with two different
spontaneous allelic mutations in Sharpin where both were functional null alleles, one on a B6
substrain and the other on a BALB congenic strain, the latter being more severely affected [6].
To recapitulate this, B6- and BALB-CMV-cre-recombinases transgenic mice were crossed with
the B6.Cg conditional Sharpin allele. This was initially set up using the BALB allele as it was
the only one available at the time. When the B6 allele became available, it was used. Both had
similar lesions at the gross, hematological, and histopathological levels; however, the B6 strain
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was more severely affected than the BALB, opposite that of the spontaneous null alleles of
Sharpin. These results limited comparative studies at older ages. Since the overall disease was
the same with only differences in life expectancy, identification of modifier genes could be rel-
atively difficult. Alternatively, the effect of the Sharpin null mutation is quite severe and over-
riding more subtle differences in phenotyping. This observation allows one to be less
concerned about strain background in the crosses used in this study than in other studies
where background effects play a major role.
Restricting the loss of SHARPIN expression to specific cell types resulted in different phe-
notypes. Absence of SHARPIN expression in adipocytes did not result in an abnormal pheno-
type. By contrast, skin disease was severe in the ubiquitously and keratin (Krt14) inactivated
Sharpin and mild in the S100a4 Sharpin-/- cross. Verification of the expression of S100a4-cre-
recombinase revealed that it was expressed in keratinocytes, albeit less so than for the
Krt14-cre, but not in skin fibroblasts. While S100A4 is still sometimes published as fibroblast-
specific protein [54], results shown here reveal this is not the case, rather it is expressed in the
epidermal and infundibular keratinocytes. This is also the case in human skin where S100A4 is
expressed in the hair follicle, Langerhans cells, and melanocytes [69, 70]. The gene/protein
name has been changed to S100 calcium binding protein A4 in Mouse Genome Informatics
(http://www.informatics.jax.org; 22 Jan 2020). S100a4-cre-recombinase expression in kerati-
nocytes explains why lesions were present in the skin. Reduced expression of the cre-recombi-
nase in the mouse skin for the S100a4 versus the Krt14may explain the qualitative and
quantitative differences between these two crosses. While lesions were observed in mice of
both sexes at relatively the same levels, in the S100a4 Sharpin-/- joint lesions were more severe
than in the other crosses and more severe in the females. The knee joint was less often affected
or less severely affected in males. Shoulder joints were more severely affected. S100A4 is
involved in promoting cancer progression and metastasis, fibrosis, inflammation, immune
response, neuroprotection, angiogenesis, and some common non-tumor diseases including
being upregulated in cells infiltrating rheumatoid arthritis synovial tissue [71, 72]. Images on
the cre-recombinase website (http://www.informatics.jax.org/recombinase/specificity?id=
MGI:3712292&system=skeletal+system; 6 Feb 2020) reveal that S100a4 is expressed in bone
and bone marrow which helps to partially explain the joint specific lesions in these mice. Two
factors were probably involved in the variability in arthritis between individuals. One is that
inbred strains could not be used as the cre-recombinase transgenic mice were not on the same
background or were mixed backgrounds. This alone results in phenotypic variability. The sec-
ond was that since some of the crosses were very detrimental, all mice were evaluated at 6
weeks of age as that was the only age at which representative mutant mice could be obtained
from all the crosses. Lesions developed more consistently with age in those that were destined
to develop lesions in affected organs, especially in the joints. This work needs to be repeated in
detail to determine what cell types in the bone marrow and joints that express S100a4. This
cross provides a useful model for studying autoinflammatory arthritis. These observations
combined with protein localization using immunohistochemistry support keratinocytes as the
primary cell type involved in many of the lesions, particular the skin.
The dermatitis in Sharpincpdm/cpdm mice has many features in common with atopic dermati-
tis, but is not associated with an increase of serum IgE [3]. Indeed, previous work demon-
strated that the dermatitis develops in the absence of functional B and T cells [6]. Mutant
Sharpincpdm/cpdm mice have decreased or undetectable serum IgG, IgA, and IgE and a modest
increase of serum IgM [3]. This indicates a defect in isotype switching consistent with the
impairment of NFkB signaling upon activation of B cells with anti-CD40 [12–14]. Remarkably,
selective deletion of Sharpin in keratinocytes is sufficient to recapitulate the dermatitis of mice
with the spontaneous Sharpinmutation, and this was associated with a marked increase of
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serum IgE as the B cells in Krt14 Sharpin-/- mice were able to undergo isotype switching. The
mechanism that underlies the increase of serum IgE is not entirely clear, but it likely involves
increased secretion of IL18. The serum concentration of IL18 was increased dramatically in
Krt14 Sharpin-/- mice. Transgenic mice with overexpression of IL18 in the epidermis develop a
type 2 inflammatory dermatitis and increase of serum IgE [73]. In the absence of STAT6,
required for signaling through the IL4 and IL13 receptor, these mice had undetectable IgE, but
developed a similar dermatitis indicating that the IgE was not necessary for the development
of the dermatitis. A direct role for IL18 in the increase of IgE is further supported by the obser-
vation that daily injection of IL18 induces an increase of serum IgE in an IL4-dependent man-
ner [58]. An increase of serum IL18 has also been observed in human patients with atopic
dermatitis and it has been suggested that IL18 can serve as a biomarker of disease severity [74].
TSLP and IL33 can be secreted by epithelial cells upon damage or stress and induce local
inflammation through the activation of dendritic cells, type 2 innate lymphoid cells (ILC2),
basophils, and mast cells [75]. Both Tslp and Il33mRNA were increased in the skin of BALB-
and B6-CMV Sharpin-/- mice, but only TslpmRNA was increased in the skin of Krt14 Shar-
pin-/- and S100a4 Sharpin-/- mice. TSLP and IL33 both play a role in the induction of atopic
dermatitis-like skin lesions following topical application of the vitamin D analogue calcipotriol
[76, 77], and overexpression of TSLP and IL33 in the epidermis of transgenic mice induced a
type 2 inflammatory response with accumulation of mast cells, eosinophils, and an increase of
serum IgE [78, 79]. The expression of TSLP and IL33 is increased in the skin of human patients
with atopic dermatitis [80, 81]. The dermatitis in SHARPIN-deficient mice is associated with
apoptosis of keratinocytes [1]. The apoptosis and dermatitis were inhibited by deletion of
TNFR1 [15, 16, 82]. This suggests that keratinocyte damage in the absence of SHARPIN may
lead to release of TSLP and IL33, which initiate the dermatitis through the activation of ILC2
and basophils.
CCL11 and CCL24 are both ligands of the chemokine receptor CCR3 expressed on eosino-
phils and are involved in the recruitment and activation of eosinophils [83]. They are both
secreted by fibroblasts upon stimulation with IL4 and IL13, but they have overlapping but dis-
tinct expression patterns and functions. Using genetically engineered mice, it was demon-
strated that CCL24 had a dominant role in the recruitment of eosinophils into the airways of
mice in an asthma model [84]. The expression of CCL24 was more consistently and strongly
increased compared with CCL11 in the skin of mutant mice suggesting a more important role
for CCL24 in the dermatitis of SHARPIN-deficient mice.
The dermatitis in mutant Sharpincpdm/cpdm mice is characterized by a marked increase of
the number of mast cells. It was therefore surprising that the expression of mast cell proteases
Mcpt4 andMcpt5, expressed in dermal connective tissue mast cells [61], was not or only mini-
mally increased in the skin of mutant mice. However, treatment of bone marrow-derived mast
cells with IL4 decreased the expression ofMcpt4 [85], suggesting that the expression of mast
cell proteases is affected by the cytokines in a type 2 inflammatory environment. The mast cell
protease 9 was initially reported to be exclusively expressed in mast cells isolated from the
uterus in mice [63]. However, it can be expressed by other mast cells [64], and we show here
that its expression is increased in the skin of mutant mice with dermatitis. The mast cell prote-
ase 8 is used as a marker of basophils based on the exclusive expression in these cells [62],
although a report suggests that it is also expressed in granulocyte-macrophage progenitor cells
[86]. Nevertheless, in the skinMcpt8 expression is associated with basophils, and the marked
increased expression ofMcpt8 suggests an increased number of basophils in the skin. Both
TSLP and IL33 enhance the production and activation of basophils [87, 88].
Spontaneous Sharpinmutations that arose in laboratory mice [2] provided useful models to
dissect linear ubiquitin chain assembly complex (LUBAC) which is required for activation of
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the NFkB signaling pathway [12–14, 89] and they continue to do so [16, 27, 30, 34, 90]. The
conditional Sharpin null allele, which is publicly available at The Jackson Laboratory, provides
a new tool to further investigate this molecular pathway. Refining the mouse model, especially
using the S100a4-cre-recombinase transgenic mouse, provides tools to investigate autoinflam-
matory arthritis and atopic dermatitis.
Supporting information
S1 Fig. Cre-recombinase expression for the different promotors used. Krt14-cre was
expressed throughout the epidermis and hair follicles (A). S100A4-cre, which was expected to
be limited to fibroblasts, was strongly expressed in keratinocytes of the epidermis and parts of
the hair follicle (B). Adipoqu-cre expression was limted to white and brown adipose tissue (C).
(TIF)
S2 Fig. Change in body weight by cross. Males were consistently heavier than females. Mice
with severe skin or skin and visceral lesions had moderate to severe weight loss as they aged.
(TIF)
S3 Fig. Peripheral blood values. White blood cells in peripheral blood of wild-type (WT),
Krt14 Sharpin-/-(Krt14-Sharpin), and S100a4 Sharpin-/- (S100a4-Sharpin) mice. Bars represent
the mean + SEM. � P < 0.05; �� P< 0.01.
(TIF)
S4 Fig. Limiting ridge and forestomach histology. The normal forestomach of mice is lined
by stratified squamous epithelium. The epithelium forms a papillomatous structure, stratified
squamous epithelium on a fibrovascular stalk, called the limiting ridge that forms a junction
with the glandular stomach. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the con-
ditional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous Sharpincpdm/
cpdm mice (B). The squamous epithelia were moderately to severely acanthotic with orthokera-
totic hyperkeratosis and moderate apoptosis of keratinocytes, very similar to epidermal
changes in affected mice. While KRT14 is expressed in the forestomach by immunohistochem-
istry (data not shown) similar to where SHARPIN is expressed (Fig 2N) the forestomach was
normal in the Krt14-cremice (E). Mice carrying the S100a4-cre (F) or Adipoq-cre (G) all had
normal forestomach anatomy. Low magnification 100X, high magnification 400X.
(TIF)
S5 Fig. Liver histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the con-
ditional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous Sharpincpdm/
cpdm mice (B). A mixed inflammatory cell infiltrate was present surrounding large hepatic
veins and portal triads. Fibrosis was a feature of the inflammation around large veins. Mice
carrying the Krt14-cre (E), S100a4-cre (F), or Adipoq-cre (G) all had normal livers. Low magni-
fication 40X, high magnification 40X.
(TIF)
S6 Fig. Lung histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the con-
ditional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous Sharpincpdm/
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cpdm mice (E). There was a mixed inflammatory cell infiltrate around the bronchioles and pul-
monary veins. Mice that were Krt14 (E), S100a4 (F), or Adipoq Sharpin-/- (G) all had normal
lungs. Low magnification 40X, high magnification 400X.
(TIF)
S7 Fig. Shoulder joint. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the con-
ditional Sharpin gene (Sharpin-/-) (C, D) had lesions similar to but less severe than in the
spontaneous Sharpincpdm/cpdm mice (B). The soft tissue surrounding the joint capsule had mild
infiltration by granulocytes. Granulocytes and fibrin were present within the joint space.
Severity varied between individuals with some males having more severe lesions. Krt14 Shar-
pin-/- mice were normal (E). S100a4 Sharpin-/- consistently had severe lesions (F). Adipoq Shar-
pin-/- mice were unaffected. Low magnification 40X, high magnification 400X.
(TIF)
S8 Fig. Knee joint histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the condi-
tional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous Sharpincpdm/cpdm
mice (B). The soft tissue surrounding the joint capsule had mild infiltration by granulocytes.
Granulocytes were present within the joint space but were few in number. Krt14 (E) and Adipoq
Sharpin-/- (G) joints were unaffected. However, joint lesions were more prominent and severe
in the S100a4-cremice (F) but less so than in the knee or temporomandibular joints. Low mag-
nification 40X, high magnification 400X.
(TIF)
S9 Fig. Middle ear histology. Female mice, 6 weeks of age, carrying any of the cre-recombi-
nase transgenes but no or only one copy of the conditional Sharpin-/- gene were normal (A)
having middle ears with no evidence of inflammation. By contrast, mice homozygous for the
spontaneous Sharpincpdm/cpdm mutation consistently had moderate to severe mixed inflamma-
tory cells in the middle ear and surrounding soft tissues (B). Mice carrying one or two copies
of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene
(Sharpin-/-) (C, D) also had middle ear inflammation. Mice carrying the Krt14 (E), S100a4 (F),
or Adipoq Sharpin-/- (G) all had normal, unaffected, middle ears. Low magnification 40X, high
magnification 400x.
(TIF)
S10 Fig. Peyer’s patch histology. Female mice, 6 weeks of age, carrying any of the cre-recom-
binase transgenes but no or only one copy of the conditional Sharpin-/- gene were normal (A)
having Peyer’s patches in their small intestines. Mice carrying one or two copies of the ubiqui-
tously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin-/-) (C,
D) had lesions identical to the spontaneous Sharpincpdm/cpdm mice (B). At this age either there
was no evidence of Peyer’s patches (C, D) or remnants effaced by eosinophils (B, high mag).
Mice carrying the Krt14 (E), S100a4 (F), or Adipoq Sharpin-/- (G) all had normal Peyer’s
patches. Low magnification 40X, high magnification 400X.
(TIF)
S11 Fig. Spleen histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase
transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice car-
rying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the
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conditional Sharpin gene (Sharpin-/-) (C, D) had lesions identical to the spontaneous Shar-
pincpdm/cpdm mice (B). In all 3 of these groups the spleen had severely disrupted white pulp
microarchitecture. There was no separate T- and B-cell areas, lack of follicles, marginal zone,
and follicular dendritic cells [91]. Mice carrying the Krt14 (E), S100a4 (F), or Adipoq (G) all
had normal spleens. Low magnification 40X, high magnification 400X.
(TIF)
S12 Fig. Cervical lymph node histology. Female mice, 6 weeks of age, carrying any of the cre-
recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal
(A). Mice homozygous for the spontaneous chronic proliferative dermatitis (Sharpincpdm/cpdm)
null mutation had marked lymphoid depletion with effacement of the lymph node by eosino-
phils (B). Mice carrying one or two copies of the ubiquitously expressing CMV-cre on either
the BALB (C) or B6 (D) background and homozygous for the conditional Sharpin gene (Shar-
pin-/-) had lesions identical to the spontaneous Sharpincpdm/cpdm mice (B). All lymph nodes
throughout the body were similarly affected. The cortex and follicles were missing, effaced by a
population of granulocytes that were primarily eosinophils. Occasionally areas of the medulla
had fibrin deposition and necrosis in the regions where follicles are usually found, as shown
for Sharpincpdm/cpdm (B, higher magnification). Mice carrying the Krt14 (E), S100a4 (F), or Adi-
poq Sharpin-/- (G) all had normal lymph nodes throughout the body. Low magnification 40X,
high magnification 400X.
(TIF)
S13 Fig. Serum immunoglobulins in 5–7 week old WT and Sharpincpdm/cpdm mice. Bars rep-
resent the mean ± SE of 6 mice/group. � p< 0.05.
(TIF)
S14 Fig. Expression of mRNA of Chil3 in wild type (WT) and the indicated mutant mice.
Bars represent the mean + SEM of fold change in gene expression in mutant vs. WT mice. ���
P< 0.001.
(TIF)
S15 Fig. Original uncropped and unadjusted images underlying results reported in Fig 1.
(TIF)
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